Elsevier

Neuropharmacology

Volume 34, Issue 7, July 1995, Pages 713-721
Neuropharmacology

General paper
Therapeutic brain concentration of the NMDA receptor antagonist amantadine

https://doi.org/10.1016/0028-3908(95)00056-CGet rights and content

Abstract

Amantadine (1-amino-adamantane) is clinically used for the management of Parkinson's disease and drug-induced extrapyramidal symptoms. It has previously been shown that amantadine is a low-affinity uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with rapid blocking and unblocking channel kinetics (Ki-value at the PCP binding site = 10 μM). The aim of the present studies was to estimate concentrations of amantadine in the central nervous system under therapeutic conditions. In homogenates of postmortem human brain tissue the amantadine concentration appeared to be homogeneously distributed over a wide range of brain areas. Amantadine concentration increased with duration of treatment and decreased with drug-free time. When the duration of treatment was ≥ 10 days and drug-free time ≤ 3 days, mean amantadine concentrations in postmortem brain tissue ranged from 48.2 to 386 μM. In contrast to brain tissue, amantadine concentration in cerebrospinal fluid (CSF) and serum was in the low micromolar range (< 17 μM). CSF and serum total values were highly correlated to each other and were always lower in CSF. The mean CSF/serum ratio for total amantadine was 0.76. To further estimate the extracellular concentration, amantadine was determined in microdialysates in the rat striatum. At behaviorally active doses, amantadine concentration in striatal microdialysates ranged between 6 and 21 μM. These results indicate that extracellular concentrations of amantadine (CSF and serum values in patients, striatal microdialysates in the rat) are in the range of its Ki-value at the PCP binding site. Amantadine concentrations in brain tissue are much higher, probably due to intralysosomal accumulation.

References (45)

  • R. Spanagel et al.

    Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat — a pharmacokinetic microdialysis study

    Eur. J. Pharmac.

    (1994)
  • J.C. Stoof et al.

    The anti-parkinsonian drug amantadine inhibits the N-methyl-Daspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way

    Eur. J. Pharmac.

    (1992)
  • M. Weller et al.

    NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine

    Brain Res.

    (1993)
  • F.Y. Aoki et al.

    Clinical pharmacokinetics of amantadine hydrochloride

    Clin. Pharmacokinetics

    (1988)
  • W.E. Bleidner et al.

    Absorption, distribution and excretion of amantadine hydrochloride

    J. Pharmac. Exp. Ther.

    (1965)
  • M. Brenner et al.

    Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations

    J. Neural.

    (1989)
  • H.S. Chen et al.

    Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity

    J. Neurosci.

    (1992)
  • W. Danysz et al.

    Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats?—Case of amantadine and memantine

    J. Neural Transm. Park. Dis. Dement. Sect.

    (1994)
  • Duve C. de et al.

    Lysosomotropic agents

    Biochem. Pharmac.

    (1974)
  • R.T. Dean et al.

    Effects of exogenous amines on mammalian cells, with particular reference to membrane flow

    Biochem. J.

    (1984)
  • A. DiMascio et al.

    A controlled trial of amantadine in drug-induced extrapyramidal disorders

    Arch. Gen. Psychiatry

    (1976)
  • S. Fahn et al.

    Acute toxic psychosis from suicidal over-dosage of amantadine

    Arch. Neural.

    (1971)
  • Cited by (109)

    • Open and rearranged norbornane derived polycyclic cage molecules as potential neuroprotective agents through attenuation of MPP<sup>+</sup>- and calcium overload-induced excitotoxicity in neuroblastoma SH-SY5Y cells

      2020, European Journal of Medicinal Chemistry
      Citation Excerpt :

      To further validate the docking protocol, four known NMDA receptor antagonists binding at the same site as MK-801, were also docked. The molecules included phencyclidine [50], R-ketamine [50], memantine [51] and amantadine [52]. The results are summarized in Table 2 and illustrates a definite trend between binding affinity and experimental Ki value.

    • Effects of amantadine on corneal endothelium

      2019, Experimental Eye Research
    • Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including L-Dopa

      2017, International Review of Neurobiology
      Citation Excerpt :

      In 1969, Coyle and Snyder suggested that the mechanism of the therapeutic action of the anticholinergic drugs in PD is related to their ability to inhibit the neuronal reuptake of dopamine in striatal neurons, thus liberating more dopamine on striatal receptors (Coyle & Snyder, 1969). Amantadine hydrochloride is a noncompetitive antagonist of N-methyl-d-aspartate receptor with rapid blocking and unblocking kinetics (Kornhuber et al., 1995). Amantadine was originally introduced in the 1960s as an antiviral agent effective against several strains of the influenza virus (Davies et al., 1964).

    View all citing articles on Scopus
    View full text